<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:dc="http://purl.org/dc/elements/1.1/">
<channel>
<title>心血管高分期刊</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_source=Chrome&amp;utm_medium=rss&amp;fc=20230708114047&amp;utm_campaign=pubmed-2&amp;ff=20240909204819&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;v=2.18.0.post9+e462414
    <description>心血管高分期刊: Latest results from PubMed</description>
<atom:link href="https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_source=Chrome&amp;utm_medium=rss&amp;fc=20230708114047&amp;utm_campaign=pubmed-2&amp;ff=20240909204819&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;v=2.18.0.post9+e462414" rel="self"></atom:link>
<docs>http://www.rssboard.org/rss-specification</docs>
<generator>PubMed RSS feeds (2.18.0.post9+e462414)</generator>
<language>en</language>
<lastbuilddate>Tue, 10 Sep 2024 00:48:20 +0000</lastbuilddate>
<pubDate>Mon, 09 Sep 2024 06:00:00 -0400</pubDate>
<ttl>120</ttl>
<item>
<title>Heart failure with preserved ejection fraction: underdiagnosed and undertreated in patients with tricuspid regurgitation</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39250731/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240909204819&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Sep 9:ehae544. doi: 10.1093/eurheartj/ehae544. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39250731/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240909204819&v=2.18.0.post9+e462414">39250731</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae544>10.1093/eurheartj/ehae544</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39250731</guid>
<pubDate>Mon, 09 Sep 2024 06:00:00 -0400</pubDate>
<dc:creator>Khawaja M Talha</dc:creator>
<dc:creator>Marco Metra</dc:creator>
<dc:creator>Javed Butler</dc:creator>
<dc:date>2024-09-09</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Heart failure with preserved ejection fraction: underdiagnosed and undertreated in patients with tricuspid regurgitation</dc:title>
<dc:identifier>pmid:39250731</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae544</dc:identifier>
</item>
<item>
<title>Management of aortic disease in children with FBN1-related Marfan syndrome</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39250726/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240909204819&amp;v=2.18.0.post9+e462414
      <description>Marfan syndrome (MFS) is a hereditary connective tissue disorder with an estimated prevalence of 1:5000-1:10 000 individuals. It is a pleiotropic disease characterized by specific ocular, cardiovascular, and skeletal features. The most common cardiovascular complication is aortic root dilatation which untreated can lead to life-threatening aortic root dissection, mainly occurring in adult patients. Prompt diagnosis, appropriate follow-up, and timely treatment can prevent aortic events. Currently...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Sep 9:ehae526. doi: 10.1093/eurheartj/ehae526. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Marfan syndrome (MFS) is a hereditary connective tissue disorder with an estimated prevalence of 1:5000-1:10 000 individuals. It is a pleiotropic disease characterized by specific ocular, cardiovascular, and skeletal features. The most common cardiovascular complication is aortic root dilatation which untreated can lead to life-threatening aortic root dissection, mainly occurring in adult patients. Prompt diagnosis, appropriate follow-up, and timely treatment can prevent aortic events. Currently there are no specific recommendations for treatment of children with MFS, and management is greatly based on adult guidelines. Furthermore, due to the scarcity of studies including children, there is a lack of uniform treatment across different centres. This consensus document aims at bridging these gaps of knowledge. This work is a joint collaboration between the paediatric subgroup of the European Network of Vascular Diseases (VASCERN, Heritable Thoracic Aortic Disease Working Group) and the Association for European Paediatric and Congenital Cardiology (AEPC). A group of experts from 12 different centres and 8 different countries participated in this effort. This document reviews four main subjects, namely, (i) imaging of the aorta at diagnosis and follow-up, (ii) recommendations on medical treatment, (iii) recommendations on surgical treatment, and (iv) recommendations on sport participation.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39250726/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240909204819&v=2.18.0.post9+e462414">39250726</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae526>10.1093/eurheartj/ehae526</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39250726</guid>
<pubDate>Mon, 09 Sep 2024 06:00:00 -0400</pubDate>
<dc:creator>Laura Muiño-Mosquera</dc:creator>
<dc:creator>Elena Cervi</dc:creator>
<dc:creator>Katya De Groote</dc:creator>
<dc:creator>Wendy Dewals</dc:creator>
<dc:creator>Zina Fejzic</dc:creator>
<dc:creator>Kalliopi Kazamia</dc:creator>
<dc:creator>Sujeev Mathur</dc:creator>
<dc:creator>Olivier Milleron</dc:creator>
<dc:creator>Thomas S Mir</dc:creator>
<dc:creator>Dorte G Nielsen</dc:creator>
<dc:creator>Michal Odermarsky</dc:creator>
<dc:creator>Anna Sabate-Rotes</dc:creator>
<dc:creator>Annelies van der Hulst</dc:creator>
<dc:creator>Irene Valenzuela</dc:creator>
<dc:creator>Guillaume Jondeau</dc:creator>
<dc:date>2024-09-09</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Management of aortic disease in children with FBN1-related Marfan syndrome</dc:title>
<dc:identifier>pmid:39250726</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae526</dc:identifier>
</item>
<item>
<title>Quantifying Longevity After Myocardial Infarction: What Is Lost and What Is Gained</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39250540/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240909204819&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Sep 10;150(11):836-837. doi: 10.1161/CIRCULATIONAHA.124.070996. Epub 2024 Sep 9.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39250540/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240909204819&v=2.18.0.post9+e462414">39250540</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.070996>10.1161/CIRCULATIONAHA.124.070996</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39250540</guid>
<pubDate>Mon, 09 Sep 2024 06:00:00 -0400</pubDate>
<dc:creator>Neel M Butala</dc:creator>
<dc:creator>Emily M Bucholz</dc:creator>
<dc:date>2024-09-09</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Quantifying Longevity After Myocardial Infarction: What Is Lost and What Is Gained</dc:title>
<dc:identifier>pmid:39250540</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.070996</dc:identifier>
</item>
<item>
<title>Noninferiority Clinical Trials: Overview for the Clinical Cardiologist</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39250539/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240909204819&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Sep 10;150(11):823-825. doi: 10.1161/CIRCULATIONAHA.124.068928. Epub 2024 Sep 9.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39250539/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240909204819&v=2.18.0.post9+e462414">39250539</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.068928>10.1161/CIRCULATIONAHA.124.068928</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39250539</guid>
<pubDate>Mon, 09 Sep 2024 06:00:00 -0400</pubDate>
<dc:creator>Sabina A Murphy</dc:creator>
<dc:creator>Andrea Bellavia</dc:creator>
<dc:date>2024-09-09</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Noninferiority Clinical Trials: Overview for the Clinical Cardiologist</dc:title>
<dc:identifier>pmid:39250539</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.068928</dc:identifier>
</item>
<item>
<title>Genetic and Pharmacologic Inhibition of JAK1/2 Antagonizes Cardiac Fibrosis</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39250538/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240909204819&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Sep 10;150(11):899-901. doi: 10.1161/CIRCULATIONAHA.124.070340. Epub 2024 Sep 9.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39250538/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240909204819&v=2.18.0.post9+e462414">39250538</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.070340>10.1161/CIRCULATIONAHA.124.070340</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39250538</guid>
<pubDate>Mon, 09 Sep 2024 06:00:00 -0400</pubDate>
<dc:creator>Qinghang Meng</dc:creator>
<dc:creator>Bo Yang</dc:creator>
<dc:creator>Yan Qiao</dc:creator>
<dc:creator>Yingxin Wu</dc:creator>
<dc:creator>Jie Chen</dc:creator>
<dc:creator>Xinhua Lin</dc:creator>
<dc:creator>Jeffery D Molkentin</dc:creator>
<dc:date>2024-09-09</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Genetic and Pharmacologic Inhibition of JAK1/2 Antagonizes Cardiac Fibrosis</dc:title>
<dc:identifier>pmid:39250538</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.070340</dc:identifier>
</item>
<item>
<title>Targeting Fibrinolytic Inhibition for Venous Thromboembolism Treatment: Overview of an Emerging Therapeutic Approach</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39250537/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240909204819&amp;v=2.18.0.post9+e462414
      <description>Venous thrombosis and pulmonary embolism (venous thromboembolism) are important causes of morbidity and mortality worldwide. In patients with venous thromboembolism, thrombi obstruct blood vessels and resist physiological dissolution (fibrinolysis), which can be life threatening and cause chronic complications. Plasminogen activator therapy, which was developed >;50 years ago, is effective in dissolving thrombi but has unacceptable bleeding risks. Safe dissolution of thrombi in patients with...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Sep 10;150(11):884-898. doi: 10.1161/CIRCULATIONAHA.124.069728. Epub 2024 Sep 9.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Venous thrombosis and pulmonary embolism (venous thromboembolism) are important causes of morbidity and mortality worldwide. In patients with venous thromboembolism, thrombi obstruct blood vessels and resist physiological dissolution (fibrinolysis), which can be life threatening and cause chronic complications. Plasminogen activator therapy, which was developed >;50 years ago, is effective in dissolving thrombi but has unacceptable bleeding risks. Safe dissolution of thrombi in patients with venous thromboembolism has been elusive despite multiple innovations in plasminogen activator design and catheter-based therapy. Evidence now suggests that fibrinolysis is rigidly controlled by endogenous fibrinolysis inhibitors, including α2-antiplasmin, plasminogen activator inhibitor-1, and thrombin-activable fibrinolysis inhibitor. Elevated levels of these fibrinolysis inhibitors are associated with an increased risk of venous thromboembolism in humans. New therapeutic paradigms suggest that accelerated and effective fibrinolysis may be achieved safely by therapeutically targeting these fibrinolytic inhibitors in venous thromboembolism. In this article, we discuss the role of fibrinolytic components in venous thromboembolism and the current status of research and development targeting fibrinolysis inhibitors.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39250537/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240909204819&v=2.18.0.post9+e462414">39250537</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.069728>10.1161/CIRCULATIONAHA.124.069728</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39250537</guid>
<pubDate>Mon, 09 Sep 2024 06:00:00 -0400</pubDate>
<dc:creator>Satish Singh</dc:creator>
<dc:creator>Pardeep Kumar</dc:creator>
<dc:creator>Yogendra S Padwad</dc:creator>
<dc:creator>Farouc A Jaffer</dc:creator>
<dc:creator>Guy L Reed</dc:creator>
<dc:date>2024-09-09</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Targeting Fibrinolytic Inhibition for Venous Thromboembolism Treatment: Overview of an Emerging Therapeutic Approach</dc:title>
<dc:identifier>pmid:39250537</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.069728</dc:identifier>
</item>
<item>
<title>Transcatheter Aortic Valve Implantation: Two Decades of a Revolutionary and Ongoing Odyssey</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39250536/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240909204819&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Sep 10;150(11):821-822. doi: 10.1161/CIRCULATIONAHA.124.068237. Epub 2024 Sep 9.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39250536/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240909204819&v=2.18.0.post9+e462414">39250536</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.068237>10.1161/CIRCULATIONAHA.124.068237</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39250536</guid>
<pubDate>Mon, 09 Sep 2024 06:00:00 -0400</pubDate>
<dc:creator>Alain Cribier</dc:creator>
<dc:creator>Hélène Eltchaninoff</dc:creator>
<dc:date>2024-09-09</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Transcatheter Aortic Valve Implantation: Two Decades of a Revolutionary and Ongoing Odyssey</dc:title>
<dc:identifier>pmid:39250536</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.068237</dc:identifier>
</item>
<item>
<title>Divergent sensory pathways of sneezing and coughing</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39243765/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240909204819&amp;v=2.18.0.post9+e462414
      <description>Sneezing and coughing are primary symptoms of many respiratory viral infections and allergies. It is generally assumed that sneezing and coughing involve common sensory receptors and molecular neurotransmission mechanisms. Here, we show that the nasal mucosa is innervated by several discrete populations of sensory neurons, but only one population (MrgprC11^(+)MrgprA3^(-)) mediates sneezing responses to a multitude of nasal irritants, allergens, and viruses. Although this population also...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2024 Sep 4:S0092-8674(24)00900-0. doi: 10.1016/j.cell.2024.08.009. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Sneezing and coughing are primary symptoms of many respiratory viral infections and allergies. It is generally assumed that sneezing and coughing involve common sensory receptors and molecular neurotransmission mechanisms. Here, we show that the nasal mucosa is innervated by several discrete populations of sensory neurons, but only one population (MrgprC11<sup>+</sup>MrgprA3<sup>-</sup>) mediates sneezing responses to a multitude of nasal irritants, allergens, and viruses. Although this population also innervates the trachea, it does not mediate coughing, as revealed by our newly established cough model. Instead, a distinct sensory population (somatostatin [SST<sup>+</sup>]) mediates coughing but not sneezing, unraveling an unforeseen sensory difference between sneezing and coughing. At the circuit level, sneeze and cough signals are transmitted and modulated by divergent neuropathways. Together, our study reveals the difference in sensory receptors and neurotransmission/modulation mechanisms between sneezing and coughing, offering neuronal drug targets for symptom management in respiratory viral infections and allergies.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39243765/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240909204819&v=2.18.0.post9+e462414">39243765</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2024.08.009>10.1016/j.cell.2024.08.009</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39243765</guid>
<pubDate>Sat, 07 Sep 2024 06:00:00 -0400</pubDate>
<dc:creator>Haowu Jiang</dc:creator>
<dc:creator>Huan Cui</dc:creator>
<dc:creator>Mengyu Chen</dc:creator>
<dc:creator>Fengxian Li</dc:creator>
<dc:creator>Xiaolei Shen</dc:creator>
<dc:creator>Changxiong J Guo</dc:creator>
<dc:creator>George E Hoekel</dc:creator>
<dc:creator>Yuyan Zhu</dc:creator>
<dc:creator>Liang Han</dc:creator>
<dc:creator>Kangyun Wu</dc:creator>
<dc:creator>Michael J Holtzman</dc:creator>
<dc:creator>Qin Liu</dc:creator>
<dc:date>2024-09-07</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Divergent sensory pathways of sneezing and coughing</dc:title>
<dc:identifier>pmid:39243765</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2024.08.009</dc:identifier>
</item>
<item>
<title>Sex-dependent effects in the aged melanoma tumor microenvironment influence invasion and resistance to targeted therapy</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39243764/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240909204819&amp;v=2.18.0.post9+e462414
      <description>There is documented sex disparity in cutaneous melanoma incidence and mortality, increasing disproportionately with age and in the male sex. However, the underlying mechanisms remain unclear. While biological sex differences and inherent immune response variability have been assessed in tumor cells, the role of the tumor-surrounding microenvironment, contextually in aging, has been overlooked. Here, we show that skin fibroblasts undergo age-mediated, sex-dependent changes in their proliferation,...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2024 Sep 4:S0092-8674(24)00904-8. doi: 10.1016/j.cell.2024.08.013. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">There is documented sex disparity in cutaneous melanoma incidence and mortality, increasing disproportionately with age and in the male sex. However, the underlying mechanisms remain unclear. While biological sex differences and inherent immune response variability have been assessed in tumor cells, the role of the tumor-surrounding microenvironment, contextually in aging, has been overlooked. Here, we show that skin fibroblasts undergo age-mediated, sex-dependent changes in their proliferation, senescence, ROS levels, and stress response. We find that aged male fibroblasts selectively drive an invasive, therapy-resistant phenotype in melanoma cells and promote metastasis in aged male mice by increasing AXL expression. Intrinsic aging in male fibroblasts mediated by EZH2 decline increases BMP2 secretion, which in turn drives the slower-cycling, highly invasive, and therapy-resistant melanoma cell phenotype, characteristic of the aged male TME. Inhibition of BMP2 activity blocks the emergence of invasive phenotypes and sensitizes melanoma cells to BRAF/MEK inhibition.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39243764/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240909204819&v=2.18.0.post9+e462414">39243764</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2024.08.013>10.1016/j.cell.2024.08.013</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39243764</guid>
<pubDate>Sat, 07 Sep 2024 06:00:00 -0400</pubDate>
<dc:creator>Yash Chhabra</dc:creator>
<dc:creator>Mitchell E Fane</dc:creator>
<dc:creator>Sneha Pramod</dc:creator>
<dc:creator>Laura Hüser</dc:creator>
<dc:creator>Daniel J Zabransky</dc:creator>
<dc:creator>Vania Wang</dc:creator>
<dc:creator>Agrani Dixit</dc:creator>
<dc:creator>Ruzhang Zhao</dc:creator>
<dc:creator>Edwin Kumah</dc:creator>
<dc:creator>Megan L Brezka</dc:creator>
<dc:creator>Kevin Truskowski</dc:creator>
<dc:creator>Asmita Nandi</dc:creator>
<dc:creator>Gloria E Marino-Bravante</dc:creator>
<dc:creator>Alexis E Carey</dc:creator>
<dc:creator>Naina Gour</dc:creator>
<dc:creator>Devon A Maranto</dc:creator>
<dc:creator>Murilo R Rocha</dc:creator>
<dc:creator>Elizabeth I Harper</dc:creator>
<dc:creator>Justin Ruiz</dc:creator>
<dc:creator>Evan J Lipson</dc:creator>
<dc:creator>Elizabeth M Jaffee</dc:creator>
<dc:creator>Kristin Bibee</dc:creator>
<dc:creator>Joel C Sunshine</dc:creator>
<dc:creator>Hongkai Ji</dc:creator>
<dc:creator>Ashani T Weeraratna</dc:creator>
<dc:date>2024-09-07</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Sex-dependent effects in the aged melanoma tumor microenvironment influence invasion and resistance to targeted therapy</dc:title>
<dc:identifier>pmid:39243764</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2024.08.013</dc:identifier>
</item>
<item>
<title>Small-molecule GSDMD agonism in tumors stimulates antitumor immunity without toxicity</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39243763/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240909204819&amp;v=2.18.0.post9+e462414
      <description>Gasdermin-mediated inflammatory cell death (pyroptosis) can activate protective immunity in immunologically cold tumors. Here, we performed a high-throughput screen for compounds that could activate gasdermin D (GSDMD), which is expressed widely in tumors. We identified 6,7-dichloro-2-methylsulfonyl-3-N-tert-butylaminoquinoxaline (DMB) as a direct and selective GSDMD agonist that activates GSDMD pore formation and pyroptosis without cleaving GSDMD. In mouse tumor models, pulsed and low-level...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2024 Sep 2:S0092-8674(24)00898-5. doi: 10.1016/j.cell.2024.08.007. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Gasdermin-mediated inflammatory cell death (pyroptosis) can activate protective immunity in immunologically cold tumors. Here, we performed a high-throughput screen for compounds that could activate gasdermin D (GSDMD), which is expressed widely in tumors. We identified 6,7-dichloro-2-methylsulfonyl-3-N-tert-butylaminoquinoxaline (DMB) as a direct and selective GSDMD agonist that activates GSDMD pore formation and pyroptosis without cleaving GSDMD. In mouse tumor models, pulsed and low-level pyroptosis induced by DMB suppresses tumor growth without harming GSDMD-expressing immune cells. Protection is immune-mediated and abrogated in mice lacking lymphocytes. Vaccination with DMB-treated cancer cells protects mice from secondary tumor challenge, indicating that immunogenic cell death is induced. DMB treatment synergizes with anti-PD-1. DMB treatment does not alter circulating proinflammatory cytokine or leukocyte numbers or cause weight loss. Thus, our studies reveal a strategy that relies on a low level of tumor cell pyroptosis to induce antitumor immunity and raise the possibility of exploiting pyroptosis without causing overt toxicity.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39243763/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240909204819&v=2.18.0.post9+e462414">39243763</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2024.08.007>10.1016/j.cell.2024.08.007</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39243763</guid>
<pubDate>Sat, 07 Sep 2024 06:00:00 -0400</pubDate>
<dc:creator>Pietro Fontana</dc:creator>
<dc:creator>Gang Du</dc:creator>
<dc:creator>Ying Zhang</dc:creator>
<dc:creator>Haiwei Zhang</dc:creator>
<dc:creator>Setu M Vora</dc:creator>
<dc:creator>Jun Jacob Hu</dc:creator>
<dc:creator>Ming Shi</dc:creator>
<dc:creator>Ahmet B Tufan</dc:creator>
<dc:creator>Liam B Healy</dc:creator>
<dc:creator>Shiyu Xia</dc:creator>
<dc:creator>Dian-Jang Lee</dc:creator>
<dc:creator>Zhouyihan Li</dc:creator>
<dc:creator>Pilar Baldominos</dc:creator>
<dc:creator>Heng Ru</dc:creator>
<dc:creator>Hongbo R Luo</dc:creator>
<dc:creator>Judith Agudo</dc:creator>
<dc:creator>Judy Lieberman</dc:creator>
<dc:creator>Hao Wu</dc:creator>
<dc:date>2024-09-07</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Small-molecule GSDMD agonism in tumors stimulates antitumor immunity without toxicity</dc:title>
<dc:identifier>pmid:39243763</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2024.08.007</dc:identifier>
</item>
<item>
<title>TGF-β and RAS jointly unmask primed enhancers to drive metastasis</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39243762/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240909204819&amp;v=2.18.0.post9+e462414
      <description>Epithelial-to-mesenchymal transitions (EMTs) and extracellular matrix (ECM) remodeling are distinct yet important processes during carcinoma invasion and metastasis. Transforming growth factor β (TGF-β) and RAS, signaling through SMAD and RAS-responsive element-binding protein 1 (RREB1), jointly trigger expression of EMT and fibrogenic factors as two discrete arms of a common transcriptional response in carcinoma cells. Here, we demonstrate that both arms come together to form a program for lung...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2024 Aug 29:S0092-8674(24)00905-X. doi: 10.1016/j.cell.2024.08.014. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Epithelial-to-mesenchymal transitions (EMTs) and extracellular matrix (ECM) remodeling are distinct yet important processes during carcinoma invasion and metastasis. Transforming growth factor β (TGF-β) and RAS, signaling through SMAD and RAS-responsive element-binding protein 1 (RREB1), jointly trigger expression of EMT and fibrogenic factors as two discrete arms of a common transcriptional response in carcinoma cells. Here, we demonstrate that both arms come together to form a program for lung adenocarcinoma metastasis and identify chromatin determinants tying the expression of the constituent genes to TGF-β and RAS inputs. RREB1 localizes to H4K16acK20ac marks in histone H2A.Z-loaded nucleosomes at enhancers in the fibrogenic genes interleukin-11 (IL11), platelet-derived growth factor-B (PDGFB), and hyaluronan synthase 2 (HAS2), as well as the EMT transcription factor SNAI1, priming these enhancers for activation by a SMAD4-INO80 nucleosome remodeling complex in response to TGF-β. These regulatory properties segregate the fibrogenic EMT program from RAS-independent TGF-β gene responses and illuminate the operation and vulnerabilities of a bifunctional program that promotes metastatic outgrowth.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39243762/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240909204819&v=2.18.0.post9+e462414">39243762</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2024.08.014>10.1016/j.cell.2024.08.014</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39243762</guid>
<pubDate>Sat, 07 Sep 2024 06:00:00 -0400</pubDate>
<dc:creator>Jun Ho Lee</dc:creator>
<dc:creator>Francisco J Sánchez-Rivera</dc:creator>
<dc:creator>Lan He</dc:creator>
<dc:creator>Harihar Basnet</dc:creator>
<dc:creator>Fei Xavier Chen</dc:creator>
<dc:creator>Elena Spina</dc:creator>
<dc:creator>Liangji Li</dc:creator>
<dc:creator>Carles Torner</dc:creator>
<dc:creator>Jason E Chan</dc:creator>
<dc:creator>Dig Vijay Kumar Yarlagadda</dc:creator>
<dc:creator>Jin Suk Park</dc:creator>
<dc:creator>Carleigh Sussman</dc:creator>
<dc:creator>Charles M Rudin</dc:creator>
<dc:creator>Scott W Lowe</dc:creator>
<dc:creator>Tuomas Tammela</dc:creator>
<dc:creator>Maria J Macias</dc:creator>
<dc:creator>Richard P Koche</dc:creator>
<dc:creator>Joan Massagué</dc:creator>
<dc:date>2024-09-07</dc:date>
<dc:source>Cell</dc:source>
<dc:title>TGF-β and RAS jointly unmask primed enhancers to drive metastasis</dc:title>
<dc:identifier>pmid:39243762</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2024.08.014</dc:identifier>
</item>
<item>
<title>A focus on two rapidly expanding fields: cardio-oncology and genetics</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39242083/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240909204819&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Sep 7;45(34):3095-3099. doi: 10.1093/eurheartj/ehae556.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39242083/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240909204819&v=2.18.0.post9+e462414">39242083</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae556>10.1093/eurheartj/ehae556</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39242083</guid>
<pubDate>Fri, 06 Sep 2024 06:00:00 -0400</pubDate>
<dc:creator>Filippo Crea</dc:creator>
<dc:date>2024-09-06</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>A focus on two rapidly expanding fields: cardio-oncology and genetics</dc:title>
<dc:identifier>pmid:39242083</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae556</dc:identifier>
</item>
<item>
<title>A systems view of the vascular endothelium in health and disease</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39241746/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240909204819&amp;v=2.18.0.post9+e462414
      <description>The dysfunction of blood-vessel-lining endothelial cells is a major cause of mortality. Although endothelial cells, being present in all organs as a single-cell layer, are often conceived as a rather inert cell population, the vascular endothelium as a whole should be considered a highly dynamic and interactive systemically disseminated organ. We present here a holistic view of the field of vascular research and review the diverse functions of blood-vessel-lining endothelial cells during the...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2024 Sep 5;187(18):4833-4858. doi: 10.1016/j.cell.2024.07.012.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">The dysfunction of blood-vessel-lining endothelial cells is a major cause of mortality. Although endothelial cells, being present in all organs as a single-cell layer, are often conceived as a rather inert cell population, the vascular endothelium as a whole should be considered a highly dynamic and interactive systemically disseminated organ. We present here a holistic view of the field of vascular research and review the diverse functions of blood-vessel-lining endothelial cells during the life cycle of the vasculature, namely responsive and relaying functions of the vascular endothelium and the responsive roles as instructive gatekeepers of organ function. Emerging translational perspectives in regenerative medicine, preventive medicine, and aging research are developed. Collectively, this review is aimed at promoting disciplinary coherence in the field of angioscience for a broader appreciation of the importance of the vasculature for organ function, systemic health, and healthy aging.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39241746/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240909204819&v=2.18.0.post9+e462414">39241746</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2024.07.012>10.1016/j.cell.2024.07.012</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39241746</guid>
<pubDate>Fri, 06 Sep 2024 06:00:00 -0400</pubDate>
<dc:creator>Hellmut G Augustin</dc:creator>
<dc:creator>Gou Young Koh</dc:creator>
<dc:date>2024-09-06</dc:date>
<dc:source>Cell</dc:source>
<dc:title>A systems view of the vascular endothelium in health and disease</dc:title>
<dc:identifier>pmid:39241746</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2024.07.012</dc:identifier>
</item>
<item>
<title>Laws of thought in living cells</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39241745/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240909204819&amp;v=2.18.0.post9+e462414
      <description>Building biological computers is one of the most intensively pursued goals of modern synthetic biology. The new TriLoS tristate-based logic synthesis platform, published in this issue of Cell, offers a long-awaited solution to scale up the complexity of biocomputing, opening a path to move this field beyond proof-of-principle demonstrations.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2024 Sep 5;187(18):4830-4832. doi: 10.1016/j.cell.2024.08.005.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Building biological computers is one of the most intensively pursued goals of modern synthetic biology. The new TriLoS tristate-based logic synthesis platform, published in this issue of Cell, offers a long-awaited solution to scale up the complexity of biocomputing, opening a path to move this field beyond proof-of-principle demonstrations.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39241745/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240909204819&v=2.18.0.post9+e462414">39241745</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2024.08.005>10.1016/j.cell.2024.08.005</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39241745</guid>
<pubDate>Fri, 06 Sep 2024 06:00:00 -0400</pubDate>
<dc:creator>Carlise Sorenson</dc:creator>
<dc:creator>Katarzyna P Adamala</dc:creator>
<dc:date>2024-09-06</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Laws of thought in living cells</dc:title>
<dc:identifier>pmid:39241745</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2024.08.005</dc:identifier>
</item>
<item>
<title>Harnessing immune cells to leverage PARP inhibitors</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39241744/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240909204819&amp;v=2.18.0.post9+e462414
      <description>Homologous-recombination deficiency in DNA repair characterizes a unique group of cancers that are vulnerable to PARP inhibitors and cytotoxic chemotherapy. In this issue of Cell, Luo et al., demonstrated that this genetic attribute in cancer cells may reprogram tumor immune microenvironment and show promise of targeting effector-Treg cells.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2024 Sep 5;187(18):4829-4830. doi: 10.1016/j.cell.2024.07.058.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Homologous-recombination deficiency in DNA repair characterizes a unique group of cancers that are vulnerable to PARP inhibitors and cytotoxic chemotherapy. In this issue of Cell, Luo et al., demonstrated that this genetic attribute in cancer cells may reprogram tumor immune microenvironment and show promise of targeting effector-Treg cells.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39241744/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240909204819&v=2.18.0.post9+e462414">39241744</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2024.07.058>10.1016/j.cell.2024.07.058</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39241744</guid>
<pubDate>Fri, 06 Sep 2024 06:00:00 -0400</pubDate>
<dc:creator>Tian-Li Wang</dc:creator>
<dc:creator>Ie-Ming Shih</dc:creator>
<dc:date>2024-09-06</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Harnessing immune cells to leverage PARP inhibitors</dc:title>
<dc:identifier>pmid:39241744</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2024.07.058</dc:identifier>
</item>
<item>
<title>Off-the-shelf CAR-T cells could prove paradigm shifting for autoimmune diseases</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39241743/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240909204819&amp;v=2.18.0.post9+e462414
      <description>Early reports suggest that chimeric antigen receptor (CAR)-T therapy has remarkable potential for treating autoimmune disease. Current approaches rely on autologous CAR-T cells, creating a bottleneck to the broad deployment of this therapy. In this issue of Cell, Wang et al.¹ report the first use of allogeneic CAR-T cells in three patients with systemic autoimmune disease.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2024 Sep 5;187(18):4826-4828. doi: 10.1016/j.cell.2024.07.056.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Early reports suggest that chimeric antigen receptor (CAR)-T therapy has remarkable potential for treating autoimmune disease. Current approaches rely on autologous CAR-T cells, creating a bottleneck to the broad deployment of this therapy. In this issue of Cell, Wang et al.<sup>1</sup> report the first use of allogeneic CAR-T cells in three patients with systemic autoimmune disease.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39241743/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240909204819&v=2.18.0.post9+e462414">39241743</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2024.07.056>10.1016/j.cell.2024.07.056</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39241743</guid>
<pubDate>Fri, 06 Sep 2024 06:00:00 -0400</pubDate>
<dc:creator>Daniel J Baker</dc:creator>
<dc:creator>Carl H June</dc:creator>
<dc:date>2024-09-06</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Off-the-shelf CAR-T cells could prove paradigm shifting for autoimmune diseases</dc:title>
<dc:identifier>pmid:39241743</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2024.07.056</dc:identifier>
</item>
<item>
<title>Deep learning meets histones at the replication fork</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39241742/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240909204819&amp;v=2.18.0.post9+e462414
      <description>Epigenetic inheritance of heterochromatin requires transfer of parental H3-H4 tetramers to both daughter duplexes during replication. Three recent papers exploit yeast genetics coupled to inheritance assays and AlphaFold2-multimer predictions coupled to biochemistry to reveal that a replisome component (Mrc1/CLASPIN) is an H3-H4 tetramer chaperone important for parental histone transfer to daughters.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2024 Sep 5;187(18):4824-4826. doi: 10.1016/j.cell.2024.07.055.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Epigenetic inheritance of heterochromatin requires transfer of parental H3-H4 tetramers to both daughter duplexes during replication. Three recent papers exploit yeast genetics coupled to inheritance assays and AlphaFold2-multimer predictions coupled to biochemistry to reveal that a replisome component (Mrc1/CLASPIN) is an H3-H4 tetramer chaperone important for parental histone transfer to daughters.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39241742/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240909204819&v=2.18.0.post9+e462414">39241742</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2024.07.055>10.1016/j.cell.2024.07.055</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39241742</guid>
<pubDate>Fri, 06 Sep 2024 06:00:00 -0400</pubDate>
<dc:creator>Hiten D Madhani</dc:creator>
<dc:date>2024-09-06</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Deep learning meets histones at the replication fork</dc:title>
<dc:identifier>pmid:39241742</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2024.07.055</dc:identifier>
</item>
<item>
<title>Humans are unreliable models of mouse disease</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39241741/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240909204819&amp;v=2.18.0.post9+e462414
      <description>In defying conventional views that dismissed itch as trivial, I persisted in studying basophils and ILC2s in human skin and atopic dermatitis. My research on JAK inhibitors for itch ultimately led to FDA-approved drugs. This is my story of disregarding categories and definitions-a story about an unconventional path in science that emphasizes innovation over conformity.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2024 Sep 5;187(18):4814-4818. doi: 10.1016/j.cell.2024.08.006.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">In defying conventional views that dismissed itch as trivial, I persisted in studying basophils and ILC2s in human skin and atopic dermatitis. My research on JAK inhibitors for itch ultimately led to FDA-approved drugs. This is my story of disregarding categories and definitions-a story about an unconventional path in science that emphasizes innovation over conformity.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39241741/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240909204819&v=2.18.0.post9+e462414">39241741</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2024.08.006>10.1016/j.cell.2024.08.006</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39241741</guid>
<pubDate>Fri, 06 Sep 2024 06:00:00 -0400</pubDate>
<dc:creator>Brian S Kim</dc:creator>
<dc:date>2024-09-06</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Humans are unreliable models of mouse disease</dc:title>
<dc:identifier>pmid:39241741</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2024.08.006</dc:identifier>
</item>
<item>
<title>Micro-nanoplastics and cardiovascular diseases: evidence and perspectives</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39240674/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240909204819&amp;v=2.18.0.post9+e462414
      <description>Emerging evidence indicates that chemical exposures in the environment are overlooked drivers of cardiovascular diseases (CVD). Recent evidence suggests that micro- and nanoplastic (MNP) particles derived largely from the chemical or mechanical degradation of plastics might represent a novel CVD risk factor. Experimental data in preclinical models suggest that MNPs can foster oxidative stress, platelet aggregation, cell senescence, and inflammatory responses in endothelial and immune cells while...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Sep 6:ehae552. doi: 10.1093/eurheartj/ehae552. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Emerging evidence indicates that chemical exposures in the environment are overlooked drivers of cardiovascular diseases (CVD). Recent evidence suggests that micro- and nanoplastic (MNP) particles derived largely from the chemical or mechanical degradation of plastics might represent a novel CVD risk factor. Experimental data in preclinical models suggest that MNPs can foster oxidative stress, platelet aggregation, cell senescence, and inflammatory responses in endothelial and immune cells while promoting a range of cardiovascular and metabolic alterations that can lead to disease and premature death. In humans, MNPs derived from various plastics, including polyethylene and polyvinylchloride, have been detected in atherosclerotic plaques and other cardiovascular tissues, including pericardia, epicardial adipose tissues, pericardial adipose tissues, myocardia, and left atrial appendages. MNPs have measurable levels within thrombi and seem to accumulate preferentially within areas of vascular lesions. Their presence within carotid plaques is associated with subsequent increased incidence of cardiovascular events. To further investigate the possible causal role of MNPs in CVD, future studies should focus on large, prospective cohorts assessing the exposure of individuals to plastic-related pollution, the possible routes of absorption, the existence of a putative safety limit, the correspondence between exposure and accumulation in tissues, the timing between accumulation and CVD development, and the pathophysiological mechanisms instigated by pertinent concentrations of MNPs. Data from such studies would allow the design of preventive, or even therapeutic, strategies. Meanwhile, existing evidence suggests that reducing plastic production and use will produce benefits for the environment and for human health. This goal could be achieved through the UN Global Plastics Treaty that is currently in negotiation.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39240674/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240909204819&v=2.18.0.post9+e462414">39240674</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae552>10.1093/eurheartj/ehae552</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39240674</guid>
<pubDate>Fri, 06 Sep 2024 06:00:00 -0400</pubDate>
<dc:creator>Francesco Prattichizzo</dc:creator>
<dc:creator>Antonio Ceriello</dc:creator>
<dc:creator>Valeria Pellegrini</dc:creator>
<dc:creator>Rosalba La Grotta</dc:creator>
<dc:creator>Laura Graciotti</dc:creator>
<dc:creator>Fabiola Olivieri</dc:creator>
<dc:creator>Pasquale Paolisso</dc:creator>
<dc:creator>Bruno D'Agostino</dc:creator>
<dc:creator>Pasquale Iovino</dc:creator>
<dc:creator>Maria Luisa Balestrieri</dc:creator>
<dc:creator>Sanjay Rajagopalan</dc:creator>
<dc:creator>Philip J Landrigan</dc:creator>
<dc:creator>Raffaele Marfella</dc:creator>
<dc:creator>Giuseppe Paolisso</dc:creator>
<dc:date>2024-09-06</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Micro-nanoplastics and cardiovascular diseases: evidence and perspectives</dc:title>
<dc:identifier>pmid:39240674</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae552</dc:identifier>
</item>
<item>
<title>Comparison of protection against mpox following mRNA or modified vaccinia Ankara vaccination in nonhuman primates</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39236707/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240909204819&amp;v=2.18.0.post9+e462414
      <description>In 2022, mpox virus (MPXV) spread worldwide, causing 99,581 mpox cases in 121 countries. Modified vaccinia Ankara (MVA) vaccine use reduced disease in at-risk populations but failed to deliver complete protection. Lag in manufacturing and distribution of MVA resulted in additional MPXV spread, with 12,000 reported cases in 2023 and an additional outbreak in Central Africa of clade I virus. These outbreaks highlight the threat of zoonotic spillover by Orthopoxviruses. mRNA-1769, an mRNA-lipid...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2024 Sep 4:S0092-8674(24)00972-3. doi: 10.1016/j.cell.2024.08.043. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">In 2022, mpox virus (MPXV) spread worldwide, causing 99,581 mpox cases in 121 countries. Modified vaccinia Ankara (MVA) vaccine use reduced disease in at-risk populations but failed to deliver complete protection. Lag in manufacturing and distribution of MVA resulted in additional MPXV spread, with 12,000 reported cases in 2023 and an additional outbreak in Central Africa of clade I virus. These outbreaks highlight the threat of zoonotic spillover by Orthopoxviruses. mRNA-1769, an mRNA-lipid nanoparticle (LNP) vaccine expressing MPXV surface proteins, was tested in a lethal MPXV primate model. Similar to MVA, mRNA-1769 conferred protection against challenge and further mitigated symptoms and disease duration. Antibody profiling revealed a collaborative role between neutralizing and Fc-functional extracellular virion (EV)-specific antibodies in viral restriction and ospinophagocytic and cytotoxic antibody functions in protection against lesions. mRNA-1769 enhanced viral control and disease attenuation compared with MVA, highlighting the potential for mRNA vaccines to mitigate future pandemic threats.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39236707/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240909204819&v=2.18.0.post9+e462414">39236707</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2024.08.043>10.1016/j.cell.2024.08.043</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39236707</guid>
<pubDate>Thu, 05 Sep 2024 06:00:00 -0400</pubDate>
<dc:creator>Eric M Mucker</dc:creator>
<dc:creator>Alec W Freyn</dc:creator>
<dc:creator>Sandra L Bixler</dc:creator>
<dc:creator>Deniz Cizmeci</dc:creator>
<dc:creator>Caroline Atyeo</dc:creator>
<dc:creator>Patricia L Earl</dc:creator>
<dc:creator>Harini Natarajan</dc:creator>
<dc:creator>Genesis Santos</dc:creator>
<dc:creator>Tiffany R Frey</dc:creator>
<dc:creator>Rafael H Levin</dc:creator>
<dc:creator>Anusha Meni</dc:creator>
<dc:creator>Guha A Arunkumar</dc:creator>
<dc:creator>Daniel Stadlbauer</dc:creator>
<dc:creator>Patricia A Jorquera</dc:creator>
<dc:creator>Hamilton Bennett</dc:creator>
<dc:creator>Joshua C Johnson</dc:creator>
<dc:creator>Kath Hardcastle</dc:creator>
<dc:creator>Jeffrey L Americo</dc:creator>
<dc:creator>Catherine A Cotter</dc:creator>
<dc:creator>Jeff W Koehler</dc:creator>
<dc:creator>Christopher I Davis</dc:creator>
<dc:creator>Joshua D Shamblin</dc:creator>
<dc:creator>Kristin Ostrowski</dc:creator>
<dc:creator>Jo Lynne Raymond</dc:creator>
<dc:creator>Keersten M Ricks</dc:creator>
<dc:creator>Andrea Carfi</dc:creator>
<dc:creator>Wen-Han Yu</dc:creator>
<dc:creator>Nancy J Sullivan</dc:creator>
<dc:creator>Bernard Moss</dc:creator>
<dc:creator>Galit Alter</dc:creator>
<dc:creator>Jay W Hooper</dc:creator>
<dc:date>2024-09-05</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Comparison of protection against mpox following mRNA or modified vaccinia Ankara vaccination in nonhuman primates</dc:title>
<dc:identifier>pmid:39236707</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2024.08.043</dc:identifier>
</item>
<item>
<title>Transfemoral or surgical aortic valve replacement in young low-risk patients with tricuspid and bicuspid aortic valve stenosis</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39235157/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240909204819&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Sep 5:ehae537. doi: 10.1093/eurheartj/ehae537. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39235157/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240909204819&v=2.18.0.post9+e462414">39235157</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae537>10.1093/eurheartj/ehae537</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39235157</guid>
<pubDate>Thu, 05 Sep 2024 06:00:00 -0400</pubDate>
<dc:creator>Niklas Schofer</dc:creator>
<dc:creator>Stefan Blankenberg</dc:creator>
<dc:date>2024-09-05</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Transfemoral or surgical aortic valve replacement in young low-risk patients with tricuspid and bicuspid aortic valve stenosis</dc:title>
<dc:identifier>pmid:39235157</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae537</dc:identifier>
</item>





























</channel>
</rss>